SCHEMBL5545513

SCHEMBL5545513

CNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(C)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
HIF1A Q16665 7/20 0.43
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
CNR2 P34972 1/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 2/20 0.39
TP53 P04637 2/20 0.39
NLRP3 Q96P20 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 1/20 0.38
USP2 O75604 1/20 0.38
HTT P42858 1/20 0.38
CRHBP P24387 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546689 0.91 MEN1 (0.56) MEN1KMT2AHIF1AL3MBTL1NPC1
Gsk-364735 SCHEMBL5545304 0.89 KDM4E (0.53) MEN1KMT2AHIF1AL3MBTL1NPC1
SCHEMBL27686101 0.88 MEN1 (0.44) MEN1KMT2AHIF1AL3MBTL1CNR2
SCHEMBL5547282 0.88 MEN1 (0.51) MEN1KMT2AHIF1AL3MBTL1NPC1
SCHEMBL5547387 0.88 MEN1 (0.51) MEN1KMT2AHIF1AL3MBTL1NPC1
Gsk-364735 SCHEMBL5545803 0.88 KDM4E (0.52) MEN1KMT2AHIF1AL3MBTL1NPC1
SCHEMBL5539034 0.88 MEN1 (0.51) MEN1KMT2AHIF1AL3MBTL1NPC1
SCHEMBL4718024 0.88 MEN1 (0.51) MEN1KMT2AHIF1AL3MBTL1NPC1
SCHEMBL5545334 0.88 L3MBTL1 (0.42) MEN1KMT2AL3MBTL1CNR2ALDH1A1
SCHEMBL5540950 0.88 MEN1 (0.48) MEN1KMT2AHIF1AL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 MEN1 4802/4885KMT2A 502/4885HIF1A 3928/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 MEN1 4837/4885KMT2A 819/4885HIF1A 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.